CORNERSTONE INVESTORS

Assuming the Offer Price of HK$14.00 (being the high-end of the Offer Price range set
out
in this prospectus),
the total aggregate number of Shares to be subscribed for by
Greenwoods will be 11,183,000 Shares (rounded down to the nearest whole board lot and
calculated based on the conversion of the investment amount made in US$ being converted at
the rate of US$1.000 to HK$7.8282 for illustrative purposes only), representing approximately
4.73% of the Offer Shares and approximately 1.00% of the Shares in issue immediately upon
completion of the Global Offering, assuming the Over-allotment Option is not exercised and
no shares are issued pursuant to the Equity Plans.

4.

LAV Biosciences Fund IV, L.P.

LAV Biosciences Fund IV, L.P. (“LAV Biosciences”) is a Cayman exempted limited
partnership fund managed by LAV Management Co., Ltd. and its affiliates (“LAV”). LAV is a
leading Asia-based life science investment firm with portfolios covering all major sectors of
the biomedical and healthcare industry including biopharmaceuticals, medical devices,
diagnostics and healthcare services. LAV has offices in Shanghai and Hong Kong. For further
details, please refer to the section headed “History, Development and Corporate Structure – 4.
Information on our Pre-IPO Investors”.

LAV Biosciences has agreed to subscribe for such number of Offer Shares (rounded down
to the nearest whole board lot) which may be purchased for an aggregate amount of
US$20,000,000 (or approximately HK$156,564,000 calculated based on the conversion rate of
US$1.000 to HK$7.8282 for illustrative purposes only) at the Offer Price.

Assuming the Offer Price of HK$12.50 (being the low-end of the Offer Price range set out
in this prospectus),
the total aggregate number of Shares to be subscribed for by LAV
Biosciences will be 12,525,000 Shares (rounded down to the nearest whole board lot and
calculated based on the conversion of the investment amount made in US$ being converted at
the rate of US$1.000 to HK$7.8282 for illustrative purposes only), representing approximately
5.30% of the Offer Shares and approximately 1.12% of the Shares in issue immediately upon
completion of the Global Offering, assuming the Over-allotment Option is not exercised and
no shares are issued pursuant to the Equity Plans.

Assuming the Offer Price of HK$13.25 (being the mid-point of the Offer Price range set
out in this prospectus), the total aggregate number of Shares to be subscribed for by LAV
Biosciences will be 11,816,000 Shares (rounded down to the nearest whole board lot and
calculated based on the conversion of the investment amount made in US$ being converted at
the rate of US$1.000 to HK$7.8282 for illustrative purposes only), representing approximately
5.00% of the Offer Shares and approximately 1.06% of the Shares in issue immediately upon
completion of the Global Offering, assuming the Over-allotment Option is not exercised and
no shares are issued pursuant to the Equity Plans.

– 362 –

